Genomic and Genetic Characterization of Prostate Tumors Treated with Neoadjuvant Intense Androgen Deprivation Therapy

Request Access

Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy

S. Wilkinson, Huihui Ye, F. Karzai, et al.. (2020). European urology. Cited 59 times. https://doi.org/10.1101/2020.09.29.20199711

A case report of multiple primary prostate tumors with differential drug sensitivity

S. Wilkinson, S. Harmon, N. Terrigino, et al.. (2020). Nature Communications. Cited 29 times. https://doi.org/10.1038/s41467-020-14657-7

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

F. Karzai, S. Walker, S. Wilkinson, et al.. (2020). Clinical Cancer Research. Cited 25 times. https://doi.org/10.1158/1078-0432.CCR-20-2344

Comparison of Approaches to Transcriptomic Analysis in Multi-Sampled Tumors

Anson T. Ku, S. Wilkinson, A. Sowalsky. (2021). bioRxiv. Cited 8 times. https://doi.org/10.1101/2021.05.11.443668

mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy.

Samuel Gold, David J. VanderWeele, S. Harmon, et al.. (2019). Urologic oncology. Cited 7 times. https://doi.org/10.1016/j.urolonc.2019.01.012
NCPI Dataset Catalog
Feedback & Support
v0.9.0-d9e5747